Human Antibody Therapeutics
The Human Antibody Therapeutics unit supports the development of therapeutic antibodies. The unit will assist by isolating human antibodies from in-house constructed IP free phage libraries towards target proteins as suggested by the partner PI. It will be of critical importance that the partner PI has substantial knowledge and know-how of the target protein/biological system, either from a clinical or basic scientific perspective. The objective is to deliver a reasonable number of candidate clones for further in vivo characterization in collaboration with the partner PI.
Services
- Generation of well-characterized human antibodies for therapy
- Selection and cloning of monoclonal, high-affinity human antibody fragments from IP free phage display libraries
- Re-cloning, expression and purification of isolated antibodies as full-length format IgG molecules
- Initial characterization of the isolated antibodies, including e.g. DNA/amino acid sequence, binding specificity and selectivity, affinity, stability, aggregation, epitope mapping
- Assessment of function and biological potency of the antibodies using in vitro assays
- Collaborate in the design of relevant assays for biological potency of the antibodies, and in the design of proof-of-concept studies
- Consulting at the pre-project proposal stage with potential partner PIs on project design
Equipment
- Highly diverse IP free human antibody phage libraries
- Fully equipped pro- and eukaryotic cell culture laboratories
- Protein purification ÄKTA systems
- Automated liquid handling VANTAGE Hamilton robot
- SPR Biacore 8K
- ELISA work station
- KingFisher Flex system
- iQue Plus flow cytometer
- NanoDSF Prometheus
- Isothermal titration calorimeter